SG10201908881PA - Fused bicyclic compounds for the treatment of disease - Google Patents

Fused bicyclic compounds for the treatment of disease

Info

Publication number
SG10201908881PA
SG10201908881PA SG10201908881PA SG10201908881PA SG 10201908881P A SG10201908881P A SG 10201908881PA SG 10201908881P A SG10201908881P A SG 10201908881PA SG 10201908881P A SG10201908881P A SG 10201908881PA
Authority
SG
Singapore
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Raju Mohan
Benjamin Pratt
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of SG10201908881PA publication Critical patent/SG10201908881PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG10201908881P 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease SG10201908881PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26

Publications (1)

Publication Number Publication Date
SG10201908881PA true SG10201908881PA (en) 2019-11-28

Family

ID=56072361

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201908881P SG10201908881PA (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease
SG11201707610PA SG11201707610PA (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201707610PA SG11201707610PA (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Country Status (16)

Country Link
US (4) US10421759B2 (cg-RX-API-DMAC7.html)
EP (2) EP3715348A1 (cg-RX-API-DMAC7.html)
JP (1) JP6843061B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180003545A (cg-RX-API-DMAC7.html)
CN (1) CN107912042A (cg-RX-API-DMAC7.html)
AU (2) AU2016238523A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017020374A2 (cg-RX-API-DMAC7.html)
CA (1) CA2980394A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002405A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017010621A2 (cg-RX-API-DMAC7.html)
HK (1) HK1249756A1 (cg-RX-API-DMAC7.html)
IL (1) IL254572A0 (cg-RX-API-DMAC7.html)
MX (1) MX370897B (cg-RX-API-DMAC7.html)
RU (2) RU2021107054A (cg-RX-API-DMAC7.html)
SG (2) SG10201908881PA (cg-RX-API-DMAC7.html)
WO (1) WO2016151403A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
JP2019520335A (ja) * 2016-05-25 2019-07-18 アカーナ・セラピューティクス・リミテッドAkarna Therapeutics, Ltd. 疾患治療用の縮合二環式化合物
MX2018014024A (es) * 2016-05-25 2019-08-29 Akarna Therapeutics Ltd Terapias de combinación con moduladores del receptor x farnesoide (fxr).
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
CN108264474B (zh) * 2018-02-09 2019-10-25 浙江师范大学 一种色胺及其衍生物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
EP1776112A4 (en) 2004-08-10 2009-11-25 Exelixis Inc HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US20090131409A1 (en) * 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090137554A1 (en) 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
JP2012503654A (ja) * 2008-09-26 2012-02-09 ワイス・エルエルシー 1,2,3,6−テトラヒドロアゼピノ[4,5−b]インドール−5−カルボキシレート核内受容体阻害剤
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2741387C2 (ru) * 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Also Published As

Publication number Publication date
WO2016151403A1 (en) 2016-09-29
MX370897B (es) 2020-01-09
JP2018510876A (ja) 2018-04-19
US20180118752A1 (en) 2018-05-03
EP3274350A1 (en) 2018-01-31
CL2017002405A1 (es) 2018-04-27
HK1249756A1 (zh) 2018-11-09
CA2980394A1 (en) 2016-09-29
SG11201707610PA (en) 2017-10-30
US10421759B2 (en) 2019-09-24
IL254572A0 (en) 2017-11-30
AU2020256301A1 (en) 2020-11-05
US20230002394A1 (en) 2023-01-05
CO2017010621A2 (es) 2018-01-31
RU2017137366A3 (cg-RX-API-DMAC7.html) 2019-07-17
RU2021107054A (ru) 2021-03-31
CN107912042A (zh) 2018-04-13
EP3715348A1 (en) 2020-09-30
MX2017012342A (es) 2018-06-11
RU2017137366A (ru) 2019-04-26
US20210214362A1 (en) 2021-07-15
JP6843061B2 (ja) 2021-03-17
AU2016238523A1 (en) 2017-11-09
BR112017020374A2 (pt) 2018-06-05
KR20180003545A (ko) 2018-01-09
US20200079782A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
ZA202004557B (en) Modulatory polynucleotides
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
PH12019501079A1 (en) Magl inhibitors
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP3303556C0 (en) COMPOSITIONS FOR THE TREATMENT OF OSTEO-CARTILAGINOUS DISORDERS
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
HK40007136A (en) Fused bicyclic compounds for the treatment of disease
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment